AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
These observations are procedural in nature and none of them are related to data integrity
The Q1 2025 also witnessed a successful launch of Allegra D
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Subscribe To Our Newsletter & Stay Updated